CardiovascularORALGeneric
ALTOPREV
LOVASTATIN
Standard Dose
20MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ALTOPREV is listed in Drugs@FDA under application 021316 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient LOVASTATIN Form and strength TABLET, EXTENDED RELEASE;ORAL - 20MG Sponsor AZURITY Submission history Latest submission status date: 2024-03-14 00:00:00.
Structured Monograph
Clinical summary
Approval overview ALTOPREV is listed in Drugs@FDA under application 021316 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LOVASTATIN Form and strength TABLET, EXTENDED RELEASE;ORAL - 20MG Sponsor AZURITY Submission history Latest submission status date: 2024-03-14 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.